Evidence map›Paper›PMID 40545559›Full record

Trial reportAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Evaluation of cognitive, functional, and behavioral effects observed in EMERGE, a phase 3 trial of aducanumab in people with early Alzheimer's disease.

Jeffrey Cummings, Sharon Cohen, Jennifer Murphy, Holly M Brothers, Mina Nejati, Fiona Forrestal, Carl de Moor, John O'Gorman, John Harrison, Judith Jaeger and 7 more

Registry-linked trialAbstract readRandomized Controlled TrialClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02484547 (A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02484547 phase3terminatednot on this map

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease

TypeinterventionalSponsorBiogenRan2015 to 2019Enrolled1,643ConditionsAlzheimer's DiseaseArmsAducanumab (BIIB037), Placebo
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jeffrey CummingsUniversity of Las Vegas, UNLV, Las Vegas, NV, USA.
Sharon CohenToronto Memory Program, Toronto, ON, Canada.
Jennifer MurphyBiogen, Cambridge, Massachusetts, USA.
Holly M BrothersBiogen, Cambridge, Massachusetts, USA.
Mina NejatiBiogen, Cambridge, Massachusetts, USA.
Fiona ForrestalBiogen, Cambridge, Massachusetts, USA.
Carl de MoorBiogen, Cambridge, Massachusetts, USA.
John O'GormanBiogen, Cambridge, Massachusetts, USA.
John HarrisonAlzheimercentrum, AUmC, Amsterdam, the Netherlands.
Judith JaegerCognitionMetrics, LLC, Stamford, Connecticut, USA.
Catherine Jane MummeryDementia Research Centre, Queen Square Institute of Neurology, University College London, London, UK.
Anton P PorsteinssonUniversity of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Michele PotashmanBiogen, Cambridge, Massachusetts, USA.
Ying TianBiogen, Cambridge, Massachusetts, USA.
Lili YangBiogen, Cambridge, Massachusetts, USA.
Ping HeBiogen, Cambridge, Massachusetts, USA.
Samantha Budd HaeberleinBiogen, Cambridge, Massachusetts, USA.

Funding

Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) CNTN - ResubmissionP20GM109025 · NIGMS · CLEVELAND CLINIC FOUNDATION · PI JESSICA KIRKLAND CALDWELL · 2015 to 2026
$22.8M
Alzheimer's Clinical Trial InnOvatioN (ACTION) InitiativeR35AG071476 · NIA · UNIVERSITY OF NEVADA LAS VEGAS · PI CUMMINGS, JEFFREY L. · 2021 to 2025
$2.9M
BiogenNIA NIH HHS R35 AG071476NIGMS NIH HHS P20 GM109025
6 · The paper itself

Abstract

introductionIn EMERGE (NCT02484547), participants receiving aducanumab had significantly less progression versus placebo on all prespecified clinical endpoints at week 78. Here, we explicate the clinical meaningfulness of these treatment effects by analyzing item-level data and the persistence of treatment benefit.

methodsParticipants with early Alzheimer's disease (AD) were stratified by apolipoprotein E (APOE) ε4 status and randomized (1:1:1) to receive low- or high-dose aducanumab, or placebo. Prespecified principal component analyses (PCAs) per the Statistical Analysis Plan were followed by post hoc examination of individual domains/items across all five clinical endpoints. Progression analysis assessed reduction in clinical decline.

resultsHigh-dose aducanumab demonstrated clinically meaningful slowing of progression across clinical endpoints measuring cognition, daily function, and behavioral symptoms. Delay of progression over 18 months was consistent across measures; treatment effects increased over time. DISCUSSION: Across multiple analyses aducanumab slowed cognitive decline, prolonged functional independence, and attenuated behavioral symptoms in participants with early AD. These outcomes comprise the elements of a clinically meaningful response to treatment. HIGHLIGHTS: Endpoints in EMERGE assessed different aspects of cognition, daily function, and behavioral symptoms. Treatment benefits were observed across subdomains on all five clinical endpoints. Aducanumab meaningfully slowed disease progression in participants with early AD.

Indexed as

Alzheimer DiseaseAntibodies, Monoclonal, HumanizedCognitionAgedApolipoprotein E4Disease ProgressionDouble-Blind MethodFemaleHumansMaleNeuropsychological TestsTreatment OutcomeaducanumabAntibodies, Monoclonal, HumanizedApolipoprotein E4Alzheimer's diseaseanti‐Aβ mAbbehavioral symptomsclinical meaningfulnesscognitive declinefunctional independencetreatment effect

Identifiers

PMID40545559
PMCPMC12183105

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.